Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Liver Fibrosis-Pipeline Review, H1 2015

Liver Fibrosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Liver Fibrosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Liver fibrosis-Pipeline Review, H1 2015', provides an overview of the Liver fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Liver fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Liver fibrosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Liver fibrosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Liver fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Liver fibrosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Liver fibrosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Liver fibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Liver Fibrosis Overview 7

Therapeutics Development 8

Pipeline Products for Liver Fibrosis-Overview 8

Pipeline Products for Liver Fibrosis-Comparative Analysis 9

Liver Fibrosis-Therapeutics under Development by Companies 10

Liver Fibrosis-Therapeutics under Investigation by Universities/Institutes 12

Liver Fibrosis-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Liver Fibrosis-Products under Development by Companies 15

Liver Fibrosis-Products under Investigation by Universities/Institutes 18

Liver Fibrosis-Companies Involved in Therapeutics Development 19

Advinus Therapeutics Ltd. 19

Angion Biomedica Corp. 20

BerGenBio AS 21

BiOrion Technologies B.V. 22

Celgene Corporation 23

Digna Biotech, S.L. 24

FibroGen, Inc. 25

Galectin Therapeutics, Inc. 26

Genfit SA 27

GenKyoTex S.A. 28

Gilead Sciences, Inc. 29

GNI Group Ltd. 30

La Jolla Pharmaceutical Company 31

LG Life Sciences, Ltd. 32

Nitto Denko Corporation 33

Pharmaxis Limited 34

Promedior, Inc. 35

Promethera Biosciences S.A. 36

ProMetic Life Sciences Inc. 37

RXi Pharmaceuticals Corporation 38

TCM Biotech International Corp 39

Vascular Biogenics Ltd. 40

Virobay Inc. 41

Liver Fibrosis-Therapeutics Assessment 42

Assessment by Monotherapy Products 42

Assessment by Target 43

Assessment by Mechanism of Action 46

Assessment by Route of Administration 48

Assessment by Molecule Type 50

Drug Profiles 52

ANG-3281-Drug Profile 52

ANG-3298-Drug Profile 53

ANG-4011-Drug Profile 54

BGB-324-Drug Profile 55

BOT-162-Drug Profile 56

BOT-191-Drug Profile 57

CC-539-Drug Profile 58

CC-90001-Drug Profile 59

CIGB-500-Drug Profile 60

CT-140-Drug Profile 61

DB-036-Drug Profile 62

DCBBO-1202-Drug Profile 63

disitertide-Drug Profile 64

Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis-Drug Profile 66

F-351-Drug Profile 67

FG-3019-Drug Profile 69

GCS-100-Drug Profile 71

GFT-505-Drug Profile 73

GKT-137831-Drug Profile 76

GKT-901-Drug Profile 77

GM-CT-01-Drug Profile 78

GM-CT-02-Drug Profile 81

GR-MD-01-Drug Profile 82

GR-MD-02-Drug Profile 83

HepaStem-Drug Profile 85

KW-0-Drug Profile 87

LC-280126-Drug Profile 88

LJPC-201-Drug Profile 90

melittin-Drug Profile 91

ND-L02s0201-Drug Profile 92

NPLC-0393-Drug Profile 94

P-17-Drug Profile 95

PBI-4050-Drug Profile 97

PRI-724-Drug Profile 98

PRM-151-Drug Profile 100

PXS-4728A-Drug Profile 102

PXS-5033A-Drug Profile 103

RXI-209-Drug Profile 104

simtuzumab-Drug Profile 105

Small Molecule for Liver Fibrosis-Drug Profile 107

Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis-Drug Profile 108

Stem Cell Therapy for Liver Fibrosis and Liver Diseases-Drug Profile 109

Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology-Drug Profile 110

TCM-808FB-Drug Profile 111

TGFTX-4 Program-Drug Profile 112

VB-201-Drug Profile 113

VBY-376-Drug Profile 115

VBY-825-Drug Profile 116

Liver Fibrosis-Recent Pipeline Updates 117

Liver Fibrosis-Dormant Projects 150

Liver Fibrosis-Discontinued Products 151

Liver Fibrosis-Product Development Milestones 152

Featured News & Press Releases 152

Appendix 159

Methodology 159

Coverage 159

Secondary Research 159

Primary Research 159

Expert Panel Validation 159

Contact Us 159

Disclaimer 160

List of Tables

Number of Products under Development for Liver Fibrosis, H1 2015 12

Number of Products under Development for Liver Fibrosis-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Development by Companies, H1 2015 (Contd..2) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Liver Fibrosis-Pipeline by Advinus Therapeutics Ltd., H1 2015 23

Liver Fibrosis-Pipeline by Angion Biomedica Corp., H1 2015 24

Liver Fibrosis-Pipeline by BerGenBio AS, H1 2015 25

Liver Fibrosis-Pipeline by BiOrion Technologies B.V., H1 2015 26

Liver Fibrosis-Pipeline by Celgene Corporation, H1 2015 27

Liver Fibrosis-Pipeline by Digna Biotech, S.L., H1 2015 28

Liver Fibrosis-Pipeline by FibroGen, Inc., H1 2015 29

Liver Fibrosis-Pipeline by Galectin Therapeutics, Inc., H1 2015 30

Liver Fibrosis-Pipeline by Genfit SA, H1 2015 31

Liver Fibrosis-Pipeline by GenKyoTex S.A., H1 2015 32

Liver Fibrosis-Pipeline by Gilead Sciences, Inc., H1 2015 33

Liver Fibrosis-Pipeline by GNI Group Ltd., H1 2015 34

Liver Fibrosis-Pipeline by La Jolla Pharmaceutical Company, H1 2015 35

Liver Fibrosis-Pipeline by LG Life Sciences, Ltd., H1 2015 36

Liver Fibrosis-Pipeline by Nitto Denko Corporation, H1 2015 37

Liver Fibrosis-Pipeline by Pharmaxis Limited, H1 2015 38

Liver Fibrosis-Pipeline by Promedior, Inc., H1 2015 39

Liver Fibrosis-Pipeline by Promethera Biosciences S.A., H1 2015 40

Liver Fibrosis-Pipeline by ProMetic Life Sciences Inc., H1 2015 41

Liver Fibrosis-Pipeline by RXi Pharmaceuticals Corporation, H1 2015 42

Liver Fibrosis-Pipeline by TCM Biotech International Corp, H1 2015 43

Liver Fibrosis-Pipeline by Vascular Biogenics Ltd., H1 2015 44

Liver Fibrosis-Pipeline by Virobay Inc., H1 2015 45

Assessment by Monotherapy Products, H1 2015 46

Number of Products by Stage and Target, H1 2015 48

Number of Products by Stage and Mechanism of Action, H1 2015 51

Number of Products by Stage and Route of Administration, H1 2015 53

Number of Products by Stage and Molecule Type, H1 2015 55

Liver Fibrosis Therapeutics-Recent Pipeline Updates, H1 2015 121

Liver Fibrosis-Dormant Projects, H1 2015 154

Liver Fibrosis-Discontinued Products, H1 2015 155

List of Figures

Number of Products under Development for Liver Fibrosis, H1 2015 12

Number of Products under Development for Liver Fibrosis-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Products, H1 2015 18

Assessment by Monotherapy Products, H1 2015 46

Number of Products by Top 10 Targets, H1 2015 47

Number of Products by Stage and Top 10 Targets, H1 2015 47

Number of Products by Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 50

Number of Products by Top 10 Routes of Administration, H1 2015 52

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 53

Number of Products by Top 10 Molecule Types, H1 2015 54

Number of Products by Stage and Top 10 Molecule Types, H1 2015 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advinus Therapeutics Ltd.

Angion Biomedica Corp.

BerGenBio AS

BiOrion Technologies B.V.

Celgene Corporation

Digna Biotech, S.L.

FibroGen, Inc.

Galectin Therapeutics, Inc.

Genfit SA

GenKyoTex S.A.

Gilead Sciences, Inc.

GNI Group Ltd.

La Jolla Pharmaceutical Company

LG Life Sciences, Ltd.

Nitto Denko Corporation

Pharmaxis Limited

Promedior, Inc.

Promethera Biosciences S.A.

ProMetic Life Sciences Inc.

RXi Pharmaceuticals Corporation

TCM Biotech International Corp

Vascular Biogenics Ltd.

Virobay Inc.

Liver fibrosis Therapeutic Products under Development, Key Players in Liver fibrosis Therapeutics, Liver fibrosis Pipeline Overview, Liver fibrosis Pipeline, Liver fibrosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com